\
&
Contact us
\
&
Contact us
This was 3 years ago
LocationBrussels
This will be the fifth edition of the Electronic Components and Systems (ECS) Brokerage Event. This two-day get-together is the perfect way to prepare your proposals for KDT-JU calls and other ECS related calls.
The preparation of project proposals and meeting potential consortium partners will be core business. Just like last years, AENEAS, EPoSS and Inside join their forces again to create a perfect environment for ECS experts from all over Europe to come together.
On-the-spot private break-out spaces, face-to-face project idea discussions, a poster exhibition area, the ECS Brokerage Event 2023 offers a wide variety of networking opportunities. How to apply? The ECS Collaboration Tool explains how to get the best out of the event!
The ECS Brokerage Event 2023 has a limited availability and first come, first serve. More information about the programme, speakers and venue can be found on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
